{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=8+Gy&page=14", "query": { "intervention": "8 Gy", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 347, "total_pages": 35, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=8+Gy&page=15&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=8+Gy&page=13&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-04T01:38:48.370Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02287428", "title": "Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Personalized NeoAntigen Peptides", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Poly-ICLC", "type": "BIOLOGICAL" } ], "intervention_types": [ "RADIATION", "BIOLOGICAL", "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2014-11", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-11-04T01:38:48.370Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02287428" }, { "nct_id": "NCT07552558", "title": "Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "HPV-Negative Squamous Cell Carcinoma" ], "interventions": [ { "name": "Hypofractionated Stereotactic Body Radiotherapy (SBRT)", "type": "RADIATION" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Ficerafusp alfa", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "BIOLOGICAL", "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2026-11-30", "completion_date": "2034-01-31", "has_results": false, "last_update_posted_date": "2026-11-03", "last_synced_at": "2026-11-04T01:38:48.370Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07552558" }, { "nct_id": "NCT01836432", "title": "Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pancreatic Cancer", "Pancreatic Carcinoma Non-resectable", "Locally Advanced Malignant Neoplasm" ], "interventions": [ { "name": "FOLFIRINOX", "type": "DRUG" }, { "name": "Algenpantucel-L Immunotherapy", "type": "BIOLOGICAL" }, { "name": "5-FU Chemoradiation", "type": "RADIATION" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Nab-Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "RADIATION" ], "sponsor": "NewLink Genetics Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 302, "start_date": "2013-05", "completion_date": "2017-03-24", "has_results": false, "last_update_posted_date": "2020-05-28", "last_synced_at": "2026-11-04T01:38:48.370Z", "location_count": 32, "location_summary": "Tucson, Arizona • Los Angeles, California • Sacramento, California + 28 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stamford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01836432" }, { "nct_id": "NCT01303705", "title": "Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Prostate Cancer", "Cancer of the Prostate", "Prostate Cancer" ], "interventions": [ { "name": "Anti-OX40", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Providence Health & Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 13, "start_date": "2010-10-14", "completion_date": "2016-07-05", "has_results": false, "last_update_posted_date": "2018-08-29", "last_synced_at": "2026-11-04T01:38:48.370Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01303705" }, { "nct_id": "NCT02908477", "title": "Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Oropharynx Cancer" ], "interventions": [ { "name": "Adjuvant Radiation Therapy", "type": "RADIATION" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 228, "start_date": "2016-10-03", "completion_date": "2024-11-15", "has_results": true, "last_update_posted_date": "2025-02-11", "last_synced_at": "2026-11-04T01:38:48.370Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02908477" }, { "nct_id": "NCT00593554", "title": "Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Lymphoblastic Leukemia", "Myelodysplasia", "Chronic Myeloid Leukemia" ], "interventions": [ { "name": "Total Body Irradiation", "type": "RADIATION" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Rabbit ATG", "type": "BIOLOGICAL" }, { "name": "Palifermin", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG", "BIOLOGICAL" ], "sponsor": "Sherif S. Farag", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 9, "start_date": "2007-08-07", "completion_date": "2017-07-28", "has_results": true, "last_update_posted_date": "2018-04-10", "last_synced_at": "2026-11-04T01:38:48.370Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00593554" }, { "nct_id": "NCT00033657", "title": "Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 97, "start_date": "2002-08-15", "completion_date": "2009-10", "has_results": true, "last_update_posted_date": "2023-06-28", "last_synced_at": "2026-11-04T01:38:48.370Z", "location_count": 23, "location_summary": "Denver, Colorado • Newark, Delaware • Gainesville, Florida + 17 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Newark", "state": "Delaware" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00033657" }, { "nct_id": "NCT01372202", "title": "CHFR Methylation Status Esophageal Cancer Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Radiotherapy", "type": "RADIATION" }, { "name": "Esophagectomy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 31, "start_date": "2011-06", "completion_date": "2014-10-01", "has_results": true, "last_update_posted_date": "2019-01-25", "last_synced_at": "2026-11-04T01:38:48.370Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01372202" }, { "nct_id": "NCT03646617", "title": "Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "Hypofractionated Radiation Therapy (HFRT)", "type": "RADIATION" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2018-11-27", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-11-04T01:38:48.370Z", "location_count": 3, "location_summary": "Lancaster, Pennsylvania • Philadelphia, Pennsylvania • Salt Lake City, Utah", "locations": [ { "city": "Lancaster", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03646617" }, { "nct_id": "NCT03516708", "title": "Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Rectal Cancer" ], "interventions": [ { "name": "Epacadostat", "type": "DRUG" }, { "name": "Short-course radiation therapy", "type": "RADIATION" }, { "name": "CAPOX chemotherapy", "type": "DRUG" }, { "name": "FOLFOX chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2020-01-06", "completion_date": "2030-08-12", "has_results": false, "last_update_posted_date": "2026-02-11", "last_synced_at": "2026-11-04T01:38:48.370Z", "location_count": 4, "location_summary": "Orange, California • Boston, Massachusetts • Detroit, Michigan + 1 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03516708" } ] }